Benazeprilat

Benazeprilat is an orally active and the active metabolite of benazepril, a carboxyl-containing ACE inhibitor with antihypertensive activity. Benazepril is a well-established antihypertensive agent, both in monoresearch and in combination with other classes of drugs including thiazide diuretics and calcium channel blockers. Benazepril is a first-line research in reducing various pathologies associated with CV risk and secondary end-organ damage[1][2][3].

Product Specifications

CAS Number

[86541-78-8]

Product Name Alternative

CGS 14831

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Angiotensin-converting Enzyme (ACE) ; Drug Metabolite; Endogenous Metabolite

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/benazeprilat.html

Purity

99.54

Solubility

DMSO : 12.5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C1[C@H](CCC2=C(C=CC=C2)N1CC(O)=O)N([C@@H](CCC3=CC=CC=C3)C(O)=O)[H]

Molecular Formula

C22H24N2O5

Molecular Weight

396.44

Precautions

H302, H315, H319, H335

References & Citations

[1]Barrios V, Antihypertensive and organ-protective effects of benazepril. Expert Rev Cardiovasc Ther. 2010 Dec;8 (12) :1653-71.|[2]Bazil MK, Hemodynamic effects of amlodipine and benazeprilat in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1993 Mar;21 (3) :405-11.|[3]Mochel JP, Capturing the dynamics of systemic Renin-Angiotensin-Aldosterone System (RAAS) peptides heightens the understanding of the effect of benazepril in dogs. J Vet Pharmacol Ther. 2013 Apr;36 (2) :174-80.